Skip to main content
Top
Published in: Calcified Tissue International 2/2018

01-08-2018 | Original Research

Prevalence of Chronic Hypoparathyroidism in a Mediterranean Region as Estimated by the Analysis of Anonymous Healthcare Database

Authors: Luisella Cianferotti, Simone Parri, Giorgio Gronchi, Gemma Marcucci, Cristiana Cipriani, Jessica Pepe, Marco Raglianti, Salvatore Minisola, Maria Luisa Brandi

Published in: Calcified Tissue International | Issue 2/2018

Login to get access

Abstract

Epidemiological data on prevalence and incidence of chronic hypoparathyroidism are still scarce. This study aimed to establish prevalence of chronic hypoparathyroidism and incidence of surgical hypoparathyroidism using the analysis of electronic anonymous public health care database. Data referred to a 5-year period (2009–2013, Region of Tuscany, Italy, as a sample representative of the whole Mediterranean/European population, estimated mean population: 3,750,000 inhabitants) were retrieved by the analysis of pharmaceutical distribution dataset, containing data related to drugs reimbursed by public health system, hospital discharge and procedures codes, and ICD9 exemption codes for chronic diseases. The application of a specific algorithm was applied to indirectly identify people with chronic hypoparathyroidism as assuming chronic therapy with active vitamin D metabolites (AVDM). The number of people taking AVDM for a period equal to or longer than 6 months till the end of the study period, with ICD9 exemption code for hypoparathyroidism, and with a disease-related discharge code were identified. Within this restricted group, patients with chronic kidney disease and osteoporosis were excluded. The indirect estimate of chronic hypoparathyroidism in a European Mediterranean subpopulation by means of the analysis of chronic therapy with AVDM was 27/100,000 inhabitants (female:male ratio = 2.2:1), with a mean age of 63.5 ± 16.7 years. The risk of developing hypoparathyroidism after neck surgery was 1.5%. While the epidemiological approaches based on disease code and hospital discharge code greatly underestimates the prevalence of hypoparathyroidism, the indirect estimate of this disease through the analysis of prescriptions of AVDM in a European region is in line with the results of studies performed in other regions of the world.
Literature
1.
go back to reference Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, Peacock M, Raffaelli M, Silva BC, Thakker RV, Vokes T, Bouillon R (2016) Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab 101:2300–2312CrossRefPubMed Shoback DM, Bilezikian JP, Costa AG, Dempster D, Dralle H, Khan AA, Peacock M, Raffaelli M, Silva BC, Thakker RV, Vokes T, Bouillon R (2016) Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab 101:2300–2312CrossRefPubMed
2.
go back to reference Clarke BL, Brown EM, Collins MT, Jüppner H, Lakatos P, Levine MA, Mannstadt MM, Bilezikian JP, Romanischen AF, Thakker RV (2016) Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab 101:2284–2299CrossRefPubMedPubMedCentral Clarke BL, Brown EM, Collins MT, Jüppner H, Lakatos P, Levine MA, Mannstadt MM, Bilezikian JP, Romanischen AF, Thakker RV (2016) Epidemiology and diagnosis of hypoparathyroidism. J Clin Endocrinol Metab 101:2284–2299CrossRefPubMedPubMedCentral
3.
go back to reference Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, Dekkers OM, European Society of Endocrinology (2015) European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173:G1–G20CrossRefPubMed Bollerslev J, Rejnmark L, Marcocci C, Shoback DM, Sitges-Serra A, van Biesen W, Dekkers OM, European Society of Endocrinology (2015) European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol 173:G1–G20CrossRefPubMed
4.
go back to reference Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP (2013) Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1:275–283CrossRefPubMed Mannstadt M, Clarke BL, Vokes T, Brandi ML, Ranganath L, Fraser WD, Lakatos P, Bajnok L, Garceau R, Mosekilde L, Lagast H, Shoback D, Bilezikian JP (2013) Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol 1:275–283CrossRefPubMed
5.
go back to reference Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT Jr (2016) Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab 101:2313–2324CrossRefPubMedPubMedCentral Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT Jr (2016) Management of hypoparathyroidism: present and future. J Clin Endocrinol Metab 101:2313–2324CrossRefPubMedPubMedCentral
6.
go back to reference Marcucci G, Della Pepa G, Brandi ML (2017) Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism. Expert Opin Drug Saf 16:617–625CrossRefPubMed Marcucci G, Della Pepa G, Brandi ML (2017) Drug safety evaluation of parathyroid hormone for hypocalcemia in patients with hypoparathyroidism. Expert Opin Drug Saf 16:617–625CrossRefPubMed
7.
go back to reference Powers J, Joy K, Ruscio A, Lagast H (2013) Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res 28:2570–2576CrossRefPubMed Powers J, Joy K, Ruscio A, Lagast H (2013) Prevalence and incidence of hypoparathyroidism in the United States using a large claims database. J Bone Miner Res 28:2570–2576CrossRefPubMed
8.
go back to reference Clarke BL, Leibson C, Emerson J, Ransom JE, Lagast H (2011) Co-morbid medical conditions associated with prevalent hypoparathyroidism: a popualtion-based study. J Bone Miner Res 26:S182 (Abstract SA1070)CrossRef Clarke BL, Leibson C, Emerson J, Ransom JE, Lagast H (2011) Co-morbid medical conditions associated with prevalent hypoparathyroidism: a popualtion-based study. J Bone Miner Res 26:S182 (Abstract SA1070)CrossRef
9.
go back to reference Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28:2277–2285CrossRefPubMed Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2013) Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study. J Bone Miner Res 28:2277–2285CrossRefPubMed
10.
go back to reference Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res 30:1738–1744CrossRefPubMed Underbjerg L, Sikjaer T, Mosekilde L, Rejnmark L (2015) The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study. J Bone Miner Res 30:1738–1744CrossRefPubMed
11.
go back to reference Astor MC, Løvås K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB, Myhre AG, Kemp EH, Nedrebø BG, Svartberg J, Husebye ES (2016) Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab 101:3045–3053CrossRefPubMedPubMedCentral Astor MC, Løvås K, Debowska A, Eriksen EF, Evang JA, Fossum C, Fougner KJ, Holte SE, Lima K, Moe RB, Myhre AG, Kemp EH, Nedrebø BG, Svartberg J, Husebye ES (2016) Epidemiology and health-related quality of life in hypoparathyroidism in Norway. J Clin Endocrinol Metab 101:3045–3053CrossRefPubMedPubMedCentral
12.
go back to reference Cipriani C, Pepe J, Biamonte F, Manai R, Biondi P, Nieddu L, Cianferotti L, Brandi ML, Minisola S (2017) The epidemiology of hypoparathyroidism in Italy: an 8-year register-based study. Calcif Tissue Int 100:278–285CrossRefPubMed Cipriani C, Pepe J, Biamonte F, Manai R, Biondi P, Nieddu L, Cianferotti L, Brandi ML, Minisola S (2017) The epidemiology of hypoparathyroidism in Italy: an 8-year register-based study. Calcif Tissue Int 100:278–285CrossRefPubMed
13.
go back to reference Cianferotti L, Cricelli C, Kanis JA, Nuti R, Reginster JY, Ringe JD, Rizzoli R, Brandi ML (2015) The clinical use of vitamin D metabolites and their potential developments: a position statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) and the international osteoporosis foundation (IOF). Endocrine 50:12–26CrossRefPubMed Cianferotti L, Cricelli C, Kanis JA, Nuti R, Reginster JY, Ringe JD, Rizzoli R, Brandi ML (2015) The clinical use of vitamin D metabolites and their potential developments: a position statement from the European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) and the international osteoporosis foundation (IOF). Endocrine 50:12–26CrossRefPubMed
14.
go back to reference Masi L (2015) Refractory hypoparathyroidism. In: Brandi ML, Brown EM (eds) Hypoparathyroidism. Springer, London, pp 279–286 Masi L (2015) Refractory hypoparathyroidism. In: Brandi ML, Brown EM (eds) Hypoparathyroidism. Springer, London, pp 279–286
15.
go back to reference Cianferotti L, Parri S, Gronchi G, Rizzuti C, Fossi C, Black DM, Brandi ML (2015) Changing patterns of prescription in vitamin D supplementation in adults: analysis of a regional dataset. Osteoporos Int 26:2695–2702CrossRefPubMed Cianferotti L, Parri S, Gronchi G, Rizzuti C, Fossi C, Black DM, Brandi ML (2015) Changing patterns of prescription in vitamin D supplementation in adults: analysis of a regional dataset. Osteoporos Int 26:2695–2702CrossRefPubMed
16.
go back to reference Goldsmith DJ, Massy ZA, Brandenburg V (2014) The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD). Semin Nephrol 34:660–668CrossRefPubMed Goldsmith DJ, Massy ZA, Brandenburg V (2014) The uses and abuses of Vitamin D compounds in chronic kidney disease-mineral bone disease (CKD-MBD). Semin Nephrol 34:660–668CrossRefPubMed
Metadata
Title
Prevalence of Chronic Hypoparathyroidism in a Mediterranean Region as Estimated by the Analysis of Anonymous Healthcare Database
Authors
Luisella Cianferotti
Simone Parri
Giorgio Gronchi
Gemma Marcucci
Cristiana Cipriani
Jessica Pepe
Marco Raglianti
Salvatore Minisola
Maria Luisa Brandi
Publication date
01-08-2018
Publisher
Springer US
Published in
Calcified Tissue International / Issue 2/2018
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-018-0405-5

Other articles of this Issue 2/2018

Calcified Tissue International 2/2018 Go to the issue